Pembrolizumab (Keytruda) can lead to long-term remission in patients with Lynch syndrome and checkpoint mutations.

“a friend that had pancreatic cancer and this was several years ago but he had lynch and i had just remembered reading a paper about how patients with lynch were more likely to have checkpoint mutations this was prior to the approval of kai trudeau but it was in trials and so we're able to get him into a trial of katruda and he turned out to be a remarkable responder and to this day he went from unresectable to cancer free which he remains about a decade later or nearly a decade later”